论文部分内容阅读
重型肝炎病情严重,并发症多,病死率高,目前治疗效果不理想,尚无满意的疗法。近年来许多研究表明,膦甲酸钠具有抑制乙肝病毒DNA聚合酶的作用,对病毒性肝炎有较好疗效。我们应用膦甲酸钠治疗重型乙型肝炎患者,取得较好疗效,报告如下。 1 临床资料 1.1 病例选择 本组30例均为1998年12月、2000年5月收治的住院患者,男21例,女9例;年龄20～55岁,平均35.4±9.9岁。包括慢性乙型肝炎(重型)和慢性乙型肝炎(重度),诊断符合1995年5月北京第5次全国传染病寄生虫病学术会议修订的标准。 1.2 治疗方法 膦甲酸钠(可耐)注射液由连云港正大天晴制药有限公司提供,每瓶2.48/100ml。在应用抗生素、门冬氨酸钾镁、促肝细胞生长素、肌苷及支持疗法的基础上应用膦甲酸钠;方法:膦甲酸钠2.4g+10％GS 100ml静滴,每日1次,连
Severe hepatitis serious illness, complications, high mortality, the current treatment is not satisfactory, there is no satisfactory treatment. In recent years, many studies have shown that foscarnet has the effect of inhibiting hepatitis B virus DNA polymerase, has a good effect on viral hepatitis. We use foscarnet treatment of patients with severe hepatitis B, achieved good effect, the report is as follows. 1 Clinical data 1.1 Case Selection This group of 30 patients were hospitalized in December 1998, May 2000 admitted to hospital, 21 males and 9 females; aged 20 to 55 years, mean 35.4 ± 9.9 years. Including chronic hepatitis B (heavy) and chronic hepatitis B (severe), the diagnosis was in line with the revised standards of the Fifth National Conference on Infectious Diseases of Parasitic Diseases, Beijing, May 1995. 1.2 treatment of foscarnet (can be resistant) injection by Lianyungang Chia Tai Fine Chemicals Co., Ltd., each bottle 2.48 / 100ml. In the application of antibiotics, potassium magnesium aspartate, hepatocyte growth-promoting hormone, inosine and supportive therapy based on the application of foscarnet; Methods: foscarnet 2.4 g + 10% GS 100ml intravenous infusion, once daily, with